GBI Research

GBI Research provides industry-leading global business intelligence solutions. Our products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports per annum across a wide range of industries. Our reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from our expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia. Key report types currently published by GBI Research include:

 

  • Market Intelligence Reports: premium analytical reports based on a combination of market data, company, deals and project content, industry surveys and additional primary and secondary research.
  • Benchmarking Reports: analytical reports comparing key financial indicators for the top 20 companies in a particular industry and geography.
  • Industry Outlook Reports: survey-based reports, revealing and analyzing the leading experts' opinions on the future of the industry covered.
  • Market Profiles: overview-level reports based on market, company and demographic data.
  • Pipeline Analysis Reports: reports analyzing the unmet need, market size and product pipeline for different disease indications, based on a detailed database of developmental products.
GBI Research
 

List of reports from GBI Research

< prev 1    3  4  5  6  7  8  9  10  
Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
5/1/2016 | published by: GBI Research
... and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident ...  |  read more...
USD 4,995
Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth
5/1/2016 | published by: GBI Research
... and approximately one-third of the US population suffers from at least one active skin condition.For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial ...  |  read more...
USD 4,995
Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market
4/21/2016 | published by: GBI Research
... marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma. ...  |  read more...
USD 4,995
Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics
4/5/2016 | published by: GBI Research
... DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by ...  |  read more...
USD 4,995
Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms
4/1/2016 | published by: GBI Research
... by abnormal social behavior and failure to recognize what is real; its symptoms are broadly divided into positive, negative and cognitive. The treatment of schizophrenia is multi-factorial and includes medical, psychological and psychosocial inputs. Antipsychotic ...  |  read more...
USD 6,995
Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics
4/1/2016 | published by: GBI Research
... cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% ...  |  read more...
USD 4,995
Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs
3/10/2016 | published by: GBI Research
... most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, ...  |  read more...
USD 6,995
Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns
3/1/2016 | published by: GBI Research
... The prevalence of asthma in the assessed countries is a prominent contributor towards the market size. In the Asia-Pacific region, the prevalence of asthma is high in the aging population and in children (Song et ...  |  read more...
USD 4,995
Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies
3/1/2016 | published by: GBI Research
... GBI Research The Asia-Pacific (APAC) Alzheimer’s disease market will grow from $3 billion in 2014 to $5.1 billion in 2021, representing a robust Compound Annual Growth Rate of 7.9%, according to business intelligence provider GBI ...  |  read more...
USD 4,995
Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes
2/16/2016 | published by: GBI Research
... The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional – ...  |  read more...
USD 6,995
Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments
2/11/2016 | published by: GBI Research
... which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the substantia nigra region of the brain. The global Parkinson's Disease (PD) prevalence was estimated at 16.1 ...  |  read more...
USD 4,995
Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence
2/4/2016 | published by: GBI Research
... most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. In the past, breast cancer occurred less in women in Asia than women in Western countries. However, ...  |  read more...
USD 4,995
Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents
2/1/2016 | published by: GBI Research
... cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. ...  |  read more...
USD 4,995
Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation
1/1/2016 | published by: GBI Research
... the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia. The main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. As the disease progresses to more advanced ...  |  read more...
USD 6,995
Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
1/1/2016 | published by: GBI Research
... by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of ...  |  read more...
USD 4,995
Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation
12/16/2015 | published by: GBI Research
... difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, ...  |  read more...
USD 6,995
Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence
12/15/2015 | published by: GBI Research
... and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, ...  |  read more...
USD 4,995
USD 464
Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation
12/1/2015 | published by: GBI Research
... survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the ...  |  read more...
USD 6,995
Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth
12/1/2015 | published by: GBI Research
... Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...  |  read more...
USD 4,995
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
12/1/2015 | published by: GBI Research
... of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is asymptomatic at its earliest stages and when symptoms do present themselves they are non-specific. There are currently no early detection ...  |  read more...
USD 4,995
COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands
11/13/2015 | published by: GBI Research
... inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world. COPD ...  |  read more...
USD 4,995
Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations
11/1/2015 | published by: GBI Research
... serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response. The resulting insulin deficiency prevents insulin-sensitive cells from carrying out essential glucose metabolism and ...  |  read more...
USD 4,995
Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth
11/1/2015 | published by: GBI Research
... men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection ...  |  read more...
USD 4,995
Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments
10/1/2015 | published by: GBI Research
... proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8–1% ...  |  read more...
USD 4,995
< prev 1    3  4  5  6  7  8  9  10  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!